Equities research analysts forecast that Catalent (NYSE:CTLT) will announce $0.39 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Catalent’s earnings. The lowest EPS estimate is $0.31 and the highest is $0.46. Catalent reported earnings per share of $0.38 during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.6%. The firm is scheduled to announce its next earnings results on Thursday, May 3rd.
On average, analysts expect that Catalent will report full year earnings of $1.66 per share for the current fiscal year, with EPS estimates ranging from $1.50 to $1.73. For the next year, analysts anticipate that the company will post earnings of $1.88 per share, with EPS estimates ranging from $1.58 to $1.97. Zacks’ earnings per share averages are an average based on a survey of analysts that follow Catalent.
Catalent (NYSE:CTLT) last announced its earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The business had revenue of $606.30 million during the quarter, compared to analysts’ expectations of $565.05 million. During the same quarter in the prior year, the firm earned $0.27 earnings per share. The business’s revenue was up 25.3% compared to the same quarter last year.
A number of brokerages have commented on CTLT. KeyCorp raised Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 target price for the company in a report on Wednesday, March 28th. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a report on Friday. UBS raised Catalent from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 21st. Raymond James Financial raised Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a report on Wednesday, March 21st. They noted that the move was a valuation call. Finally, Stephens cut Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Catalent has an average rating of “Buy” and an average price target of $45.75.
Shares of Catalent stock traded down $0.74 during mid-day trading on Friday, reaching $39.00. 677,182 shares of the stock traded hands, compared to its average volume of 910,195. Catalent has a fifty-two week low of $27.48 and a fifty-two week high of $47.87. The stock has a market capitalization of $5,298.09, a P/E ratio of 28.89, a PEG ratio of 2.29 and a beta of 1.53. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78.
In other news, SVP William Downie sold 9,082 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the sale, the senior vice president now directly owns 46,986 shares in the company, valued at $1,964,014.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.70% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of CTLT. Champlain Investment Partners LLC grew its position in Catalent by 10.9% in the fourth quarter. Champlain Investment Partners LLC now owns 3,043,715 shares of the company’s stock worth $125,036,000 after acquiring an additional 298,015 shares during the period. American Century Companies Inc. grew its position in Catalent by 755.3% in the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after acquiring an additional 2,323,971 shares during the period. Earnest Partners LLC grew its position in Catalent by 0.5% in the third quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock worth $102,601,000 after acquiring an additional 12,652 shares during the period. Brown Advisory Inc. grew its position in Catalent by 4.3% in the fourth quarter. Brown Advisory Inc. now owns 2,031,955 shares of the company’s stock worth $83,473,000 after acquiring an additional 83,441 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Catalent by 3.8% in the fourth quarter. Bank of New York Mellon Corp now owns 1,759,362 shares of the company’s stock worth $72,274,000 after acquiring an additional 64,561 shares during the period. Institutional investors and hedge funds own 99.89% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/06/analysts-expect-catalent-ctlt-will-announce-earnings-of-0-39-per-share.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.